Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study

Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study

Beschreibung

vor 13 Jahren
Background: A crucial impediment to global tuberculosis control is
the lack of an accurate, rapid diagnostic test for detection of
patients with active TB. A new, rapid diagnostic method, (Cepheid)
Xpert MTB/RIF Assay, is an automated sample preparation and
real-time PCR instrument, which was shown to have good potential as
an alternative to current reference standard sputum microscopy and
culture. Methods: We performed a clinical validation study on
diagnostic accuracy of the Xpert MTB/RIF Assay in a TB and HIV
endemic setting. Sputum samples from 292 consecutively enrolled
adults from Mbeya, Tanzania, with suspected TB were subject to
analysis by the Xpert MTB/RIF Assay. The diagnostic performance of
Xpert MTB/RIF Assay was compared to standard sputum smear
microscopy and culture. Confirmed Mycobacterium tuberculosis in a
positive culture was used as a reference standard for TB diagnosis.
Results: Xpert MTB/RIF Assay achieved 88.4% (95%CI = 78.4% to
94.9%) sensitivity among patients with a positive culture and 99%
(95%CI = 94.7% to 100.0%) specificity in patients who had no TB.
HIV status did not affect test performance in 172 HIV-infected
patients (58.9% of all participants). Seven additional cases (9.1%
of 77) were detected by Xpert MTB/RIF Assay among the group of
patients with clinical TB who were culture negative. Within 45
sputum samples which grew non-tuberculous mycobacteria the assay's
specificity was 97.8% (95%CI = 88.2% to 99.9%). Conclusions: The
Xpert MTB/RIF Assay is a highly sensitive, specific and rapid
method for diagnosing TB which has potential to complement the
current reference standard of TB diagnostics and increase its
overall sensitivity. Its usefulness in detecting sputum smear and
culture negative patients needs further study. Further evaluation
in high burden TB and HIV areas under programmatic health care
settings to ascertain applicability, cost-effectiveness, robustness
and local acceptance are required.

Kommentare (0)

Lade Inhalte...

Abonnenten

Erasmus2
München
15
15
:
: